Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 11/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 8/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30984101 | 0.75 | ADORA2A (0.56) | ADORA2AADORA1ADORA2BPIK3CD | |
| SCHEMBL30984102 | 0.75 | ADORA2A (0.56) | ADORA2AADORA1ADORA2BPIK3CD | |
| Lithium SCHEMBL30983994 | 0.74 | ADORA2A (0.55) | ADORA2AADORA1ADORA2BPIK3CD | |
| SCHEMBL30983986 | 0.66 | CYP2C19 (0.44) | ADORA2AADORA1ADORA2BADORA3PIK3CD | |
| SCHEMBL30984104 | 0.60 | ADORA2A (0.34) | ADORA2AADORA1 | |
| SCHEMBL30983894 | 0.59 | DAPK1 (0.65) | ADORA2ASCN9A | |
| Bromide SCHEMBL31626878 | 0.59 | ADORA2A (0.33) | ADORA2AADORA1 | |
| SCHEMBL30983799 | 0.55 | PDPK1 (0.33) | — | |
| SCHEMBL1755068 | 0.54 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL31269071 | 0.53 | LIMK1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4630410-A1 | POLQ INHIBITORS | Astrazeneca AB (SE) | 2025-10-15 | — | — | EP | disclosed |
| US-20240366615-A1 | POLQ INHIBITORS | ASTRAZENECA UK LIMITED (GB) | 2024-11-07 | — | — | US | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024121753-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366615-A1 | POLQ INHIBITORS | POLQ, POLG, POLB | ADORA2A 4548/4885ADORA1 4296/4885ADORA2B 4349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.